Urinary protein biomarkers in the early detection of lung cancer
Menée à partir d'échantillons urinaires prélevés sur 83 patients atteints d'un cancer du poumon non à petites cellules, sur 74 patients présentant une maladie pulmonaire bénigne, sur 77 témoins sains et sur 28 patients atteints de tuberculose, cette étude identifie des biomarqueurs permettant de détecter précocement un cancer du poumon
The early detection of lung cancer has the potential to greatly impact disease burden through the timely identification and treatment of affected individuals at a manageable stage of development. The insufficient specificity demonstrated by currently used screening and diagnostic techniques has led to intense investigation into biomarkers as diagnostic tools. Urine may represent a non-invasive alternative matrix for diagnostic biomarker development. We performed an analysis of 242 biomarkers in urines obtained from 83 NSCLC patients, 74 patients diagnosed with benign pulmonary conditions and 77 healthy donors. A large number of significant alterations were observed between the NSCLC and control groups. A multivariate analysis identified a three biomarker panel consisting of IGFBP-1, sIL-1Ra, CEACAM-1 which discriminated NSCLC from healthy controls with a SN/SP of 84/95 in an initial training set and 72/100 in an independent validation set. This panel performed well among multiple subtypes of NSCLC and early stage disease but demonstrated only limited efficacy for the discrimination of NSCLC from benign controls and limited specificity for several other cancers and tuberculosis patients. These findings demonstrate that urine biomarkers may provide screening and diagnostic properties which exceed those reported for serum biomarkers and approach a level necessary for further clinical development.
Cancer Prevention Research , résumé, 2014